TY - JOUR
T1 - Contemporary treatment of systemic lupus erythematosus
T2 - an update for clinicians
AU - Amissah-Arthur, Maame B
AU - Gordon, Caroline
PY - 2010/7
Y1 - 2010/7
N2 - The prognosis for patients with systemic lupus erythematosus (SLE) has improved significantly, with 20-year survival now approximately 80% owing partly to effective treatment. SLE treatment has evolved from the use of conventional drugs such as hydroxychloroquine and corticosteroids, nonspecific immunosuppressants including mycophenolate mofetil, to targeting selective components of the immune cascade with a view to increased efficacy, tolerability and safety profile. These novel treatments include B-cell-depleting antibodies and fusion proteins that block the costimulatory pathways of B and T cells. A discussion of these pharmacological options and ongoing research forms the basis of this review.
AB - The prognosis for patients with systemic lupus erythematosus (SLE) has improved significantly, with 20-year survival now approximately 80% owing partly to effective treatment. SLE treatment has evolved from the use of conventional drugs such as hydroxychloroquine and corticosteroids, nonspecific immunosuppressants including mycophenolate mofetil, to targeting selective components of the immune cascade with a view to increased efficacy, tolerability and safety profile. These novel treatments include B-cell-depleting antibodies and fusion proteins that block the costimulatory pathways of B and T cells. A discussion of these pharmacological options and ongoing research forms the basis of this review.
U2 - 10.1177/2040622310380100
DO - 10.1177/2040622310380100
M3 - Article
C2 - 23251736
SN - 2040-6223
VL - 1
SP - 163
EP - 175
JO - Therapeutic advances in chronic disease
JF - Therapeutic advances in chronic disease
IS - 4
ER -